Clinical Trials
Several clinical trials explore C1-mediated pathways, hereditary angioedema with C1 esterase inhibitor deficiency, pre-eclampsia, postoperative delirium, X-linked adrenoleukodystrophy, bullous pemphigoid, and antiphospholipid syndrome. Ranging from Phase 1 and Phase 3 studies to observational protocols, these trials are sponsored by commercial entities like Chugai Pharmaceutical and Takeda, as well as academic medical centers such as The Affiliated Nanjing Drum Tower Hospital. Recruitment statuses across these studies currently vary from active recruiting to not yet recruiting participants.
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT06371417 | Not yet recruiting | Antiphospholipid Syndrome (APS)|Bullous Pemphigoid (BP)|Behçet''s Syndrome (BS)|Dermatomyositis (DM)|Immune-mediated Necrotizing Myopathy (IMNM)|Immune Thrombocytopenia (ITP) |
Chugai Pharmaceutical |
2024-05-31 | Phase 1 |
| NCT06361238 | Not yet recruiting | Delirium Postoperative |
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School |
2024-04-30 | Phase 3 |
| NCT06178120 | Recruiting | X-linked Adrenoleukodystrophy |
Minoryx Therapeutics S.L. |
2024-01-02 | -- |
| NCT06317467 | Recruiting | Pre-Eclampsia |
IRCCS Burlo Garofolo |
2023-09-13 | -- |
| NCT05578417 | Recruiting | Hereditary Angioedema (HAE)|Angioedema |
Takeda |
2023-06-15 | -- |
| NCT05833620 | Not yet recruiting | Hereditary Angioedema With C1 Esterase Inhibitor Deficiency |
Hospital Universitari Vall d''Hebron Research Institute|Hospital Universitario La Paz |
2023-05 | -- |
(data from https://clinicaltrials.gov, updated on 2024-05-22)
Compliance for Clinical Use
Mechanism and Biochemical Profile
Appendix RUO and cGMP Quality Standards
| Quality Dimension | RUO (Research Use Only) | cGMP (Current Good Manufacturing Practice) |
|---|---|---|
| Clinical Applicability | Prohibited in human clinical trials or medical diagnostics. | Mandatory for human clinical trials (Phase I–III) and therapies. |
| Regulatory Status | Non-regulated grade; exempt from drug manufacturing laws. | Legally enforced by health authorities (e.g., FDA, EMA, NMPA). |
| Facility Environment | Unclassified analytical or research laboratories. | Validated Cleanrooms (ISO Class 5–8) with continuous monitoring. |
| Quality Control | Basic purity and activity testing. | Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma). |
| Process Validation | Basic equipment calibration; no process validation required. | Full qualification (IQ/OQ/PQ) and complete batch records. |
| Quality Assurance | Vendor self-declared without required formal QMS. | Mandatory QA/QC unit, Change Control, CAPA, and vendor audits. |
| Regulatory Impact | High risk of IND rejection if used as a critical raw material. | Required for IND/NDA filings, supported by Drug Master Files (DMF). |
Footnotes
Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).